Narayana Hrudayalaya Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 8 Aug 2026 | Healthcare Services | Market Cap: ₹38.9K Cr
Organic growth trajectory is established with reasonable, steady growth expected over time. Organic revenue growth is expected to sustain current growth trajectory, supported by capacity additions and new hospital launches (Page 18).
From Narayana Hrudayalaya Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,816
Market Cap
₹38.9K Cr
P/E Ratio
45.1
How does Narayana Hrudayalaya Ltd rank in Healthcare Services?
Compare Narayana Hrudayalaya Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Narayana Hrudayalaya Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.6K Cr, net profit ₹224 Cr.
Full financials →📊 Revenue & Sales Performance
- →Organic growth trajectory is established with reasonable, steady growth expected over time.
- →Revenue growth will be supported by organic expansion and selective inorganic augmentations.
- →Upcoming quarters will see uplift from new hospital capacity in Cayman and added capacity in MMRHL hospital.
- →Clinics and insurance businesses are focusing on scaling within core cities, with 50 clinics targeted next year (mainly Bangalore and Kolkata).
- →Expansion will focus on smaller hospitals (200-250 beds) clustered across cities to improve patient access rather than large flagship hospitals beyond one per city.
- →Growth is concentrated in 2-3 key cities over 5-7 years with potential for future rollouts based on proven success.
- →Insurance subsidiary to scale moderately with adequate capitalization; major spend expected on clinics rather than insurance unit.
- →No aggressive price strategy, so ARPP and revenue growth expected to be in line with historical trends.
📈 Profitability & Margins
- →Organic revenue growth is expected to sustain current growth trajectory, supported by capacity additions and new hospital launches (Page 18).
- →Improvement in EBITDA and margins anticipated, especially from new hospitals such as Gurugram and Dharamshala, with Q4 expected to be stronger (Page 4).
- →Cayman facility margins showed sequential improvement; further margin enhancement expected as full services commission by March (Pages 3-4).
- →ARPP growth projected to be moderate, reflecting a non-aggressive pricing strategy, with uplift from Cayman and capacity expansions (Page 19).
- →Dividend strategy to continue consistently, providing reasonable cash returns (Page 24).
- →Clinic and insurance verticals are growth engines but expected losses and burn will be controlled, with breakeven around 18 months and total investment capped at INR 400-500 crores over 2-3 years (Pages 14-15).
- →Target IRR on new projects is upwards of 15%, with 3-year timeline to operationalize expansions (Page 12).
🏗️ Capital Expenditure Plans
- →Current Capex is a mix of debt (about 80%) and internal accruals funding, with long-term loans of 10-20 years.
- →Brownfield capacity addition mainly involves existing hospitals, capitalizing work-in-progress and settling bills, with some spillover expected to next quarters.
- →Greenfield projects involve hospital construction, with typical timelines of 2-2.5 years for construction and 6-9 months for licensing/fitment, totaling around 3 years to operational startup.
- →Capex focus shifted from Health City expansion (extra tower) to multiple city-wide projects like HSR, Central Bangalore, and South Bangalore.
- →Expansion includes adding beds in Howrah, Barasat, and other regions, but no aggressive addition unless there is a business case.
- →IRR target for brownfield projects is above 15%.
- →Future strategic investments include expanding primary health clinics (50 clinics target in the next year) and continued growth in Cayman with new hospital operations and integrated care products.
- →Ongoing exploration for further regional/international expansion, albeit with high thresholds for new markets.
💰 Fundraising & Capital Structure
- →The company plans to fund Capex through a mix of debt and internal accruals, with about 80% of project finance coming from banks via long-term loans (10-20 years).
- →They are comfortable with Debt-EBITDA levels up to around 3 and expect to reach that level by the end of the 4th year if all planned projects proceed.
- →As new hospitals become EBITDA positive, the Debt-EBITDA ratio is expected to decline, allowing for potential further phases of expansion.
- →There is no explicit mention of raising equity or issuing bonus shares at this time; management considers current priorities and performance more important.
- →The focus remains on conservative borrowing within serviceability limits and maintaining dry powder for special situations.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Narayana Hrudayalaya Ltd Q3 FY25 results?
Organic growth trajectory is established with reasonable, steady growth expected over time. Organic revenue growth is expected to sustain current growth trajectory, supported by capacity additions and new hospital launches (Page 18).
What is Narayana Hrudayalaya Ltd share price analysis?
Narayana Hrudayalaya Ltd currently shows a neutral. The stock trades at a P/E of 45.1 with a market cap of ₹38,892 Cr. Investors should review the full earnings analysis for detailed insights.
Is Narayana Hrudayalaya Ltd planning capital expenditure?
Current Capex is a mix of debt (about 80%) and internal accruals funding, with long-term loans of 10-20 years.
Keep Narayana Hrudayalaya Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.